Your dog was diagnosed with Nasal Carcinoma (Adenocarcinoma / SCC). ~1-2% of all canine tumours. Most common nasal tumour type. Adenocarcinoma most frequent histotype. Locally invasive; distant metastasis late in disease. Dolichocephalic and mesocephalic breeds overrepresented. Compare 3 treatment options for dogs including Definitive Radiation Therapy, Palliative Radiation (Coarse Fractionation), NSAID Therapy + Supportive Care (Palliation) — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Nasal Carcinoma (Adenocarcinoma / SCC)
Canine Oncology Treatment Guide
Nasal Carcinoma (Adenocarcinoma / SCC)
Modified Adams staging (I-IV)
Epithelial
About This Cancer
Nasal carcinomas are cancers arising from the epithelial lining of the nasal cavity and paranasal sinuses. Adenocarcinoma is the most common type, followed by squamous cell carcinoma. These tumours are locally invasive, progressively destroying the delicate bone and tissue structures within the nose, and typically present with signs such as nasal discharge (often bloody), sneezing, noisy breathing, or facial deformity as the tumour expands. One important characteristic of nasal carcinomas is that while they are very destructive locally, they tend to spread to distant sites (metastasise) late in the disease course. This means that local control — particularly with radiation therapy — can provide meaningful survival benefit. A critical prognostic factor is whether the tumour has eroded through the cribriform plate (the bone separating the nasal cavity from the brain), as this significantly worsens the outlook.
Modified Adams Staging for Canine Nasal Tumours
Based on CT extent of tumour invasion
Prognostic Factors(3)
Minimum Workup(6 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.